Korro Bio Files 8-K on Operations and Financials
Ticker: KRRO · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1703647
| Field | Detail |
|---|---|
| Company | Korro Bio, Inc. (KRRO) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financials, disclosure
TL;DR
Korro Bio dropped an 8-K detailing financials and operations - check it out!
AI Summary
Korro Bio, Inc. filed an 8-K on March 26, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company, formerly known as Frequency Therapeutics, Inc., is incorporated in Delaware and headquartered in Cambridge, MA.
Why It Matters
This 8-K filing provides an update on Korro Bio's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- Korro Bio, Inc. (company) — Registrant
- March 26, 2024 (date) — Date of Report
- Frequency Therapeutics, Inc. (company) — Former Company Name
- Cambridge, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Korro Bio, Inc.?
The primary purpose of this 8-K filing is to report on Korro Bio, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 26, 2024.
What was Korro Bio, Inc.'s former company name?
Korro Bio, Inc.'s former company name was Frequency Therapeutics, Inc.
In which state is Korro Bio, Inc. incorporated?
Korro Bio, Inc. is incorporated in Delaware.
What is the address of Korro Bio, Inc.'s principal executive offices?
The address of Korro Bio, Inc.'s principal executive offices is One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA 02139.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-26 16:14:59
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share KRRO The Nasdaq Capital M
Filing Documents
- d812258d8k.htm (8-K) — 25KB
- d812258dex991.htm (EX-99.1) — 45KB
- 0001193125-24-077613.txt ( ) — 207KB
- krro-20240326.xsd (EX-101.SCH) — 3KB
- krro-20240326_lab.xml (EX-101.LAB) — 19KB
- krro-20240326_pre.xml (EX-101.PRE) — 12KB
- d812258d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Korro Bio, Inc., dated March 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KORRO BIO, INC. Date: March 26, 2024 By: /s/ Ram Aiyar Name: Ram Aiyar Title: President and Chief Executive Officer